Bibek Aryal, Surgeon-Scientist, Independent Researcher in Cancer Outcomes, shared a post on LinkedIn:
” New Paper Alert: The blood test designed to detect your cancer early – might send you chasing a ghost that was never there.
Our recent paper in Critical Reviews in Oncology/Hematology examines the unintended consequences of modern cancer biomarkers.
A patient gets a simple blood draw. The lab detects a possible cancer signal.
But a substantial percentage of those signals are never confirmed on follow-up evaluation.
For the patient:
- Weeks of fear.
- Repeated scans.
- Invasive procedures.
- Financial burden.
- Psychological trauma.
All while pursuing a cancer that may never have existed in a clinically meaningful way.
This is the ethical paradox of modern biomarkers. The technology is extraordinary, but the clinical and ethical systems surrounding it have not kept pace.
- Who governs your molecular data?
- How should clinicians communicate uncertain, AI-driven results?
- Why do breakthrough diagnostics remain inaccessible to the populations that need them most?
In the paper, we propose two conceptual frameworks – the Ethico-Clinical Cascade and the Pillars of Trust – to help address these emerging gaps.
‘The true measure of liquid biopsy will not be defined by technological sophistication alone, but by the confidence it earns: a test that clinicians can recommend and patients can embrace without hesitation, because its utility is proven, its interpretation is transparent, and its benefits are shared equitably.’
We are not anti-innovation. We are pro-accountability.”
Title: Invisible signals, visible dilemmas: The ethical frontiers of liquid biopsy in precision oncology
Authors: Bibek Aryal, Munekazu Yamakuchi, Teruto Hashiguchi
Other articles featuring Bibek Aryal on OncoDaily.
